Evidence map›Paper›PMID 32132141›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2020

Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

Johannes F E Mann, Vivian A Fonseca, Neil R Poulter, Itamar Raz, Thomas Idorn, Søren Rasmussen, Bernt Johan von Scholten, Ofri Mosenzon, LEADER Trial Investigators

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01179048. Cited by 27 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 5 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01179048 phase3completed

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

Ran2010Enrolled9,341Registered outcomes6Posted comparisons20ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo
PMID 28476871PMID 29947247PMID 24176437PMID 30851070PMID 29760228PMID 30508430PMID 30566004PMID 30566006PMID 30260088PMID 29903847PMID 25656058PMID 25275271other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 5 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  5. Pooled it
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023 · on this map
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 5 countries.

Johannes F E MannKfH Kidney Center, Munich, Germany.
Vivian A FonsecaTulane University Health Sciences Center, School of Medicine, New Orleans, Louisiana.
Neil R PoulterSchool of Public Health, Imperial College London, London, United Kingdom.
Itamar RazDiabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel; and.
Thomas IdornNovo Nordisk A/S, Søborg, Denmark.
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark.
Bernt Johan von ScholtenNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0002-1489-0636
Ofri MosenzonDiabetes Unit, Hadassah Hebrew University Hospital, Jerusalem, Israel; and.
LEADER Trial Investigators
Novo Nordisk (Denmark) · DKHebrew University of Jerusalem · ILFriedrich-Alexander-Universität Erlangen-Nürnberg · DEImperial College London · GBTulane University · US

Funding

Louisiana Clinical and Translational Science CenterU54GM104940 · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · 2025 to 2025
$3.9M
NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This

resultsOverall, serious adverse events were more frequently recorded in patients with CKD compared with those without CKD (59% versus 50%; interaction

conclusionsIn LEADER, the use of liraglutide in those with CKD was safe, with no difference between patients with and without CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov; NCT01179048 (https://clinicaltrials.gov/ct2/show/NCT01179048).

Indexed as

Glomerular Filtration RateAgedBiomarkersBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHumansHypoglycemic AgentsIncretinsKidneyLiraglutideMaleBiomarkersBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsIncretinsLiraglutidealbuminschronic kidney diseasechronic renal insufficiencyconfidence intervalscreatinineGFRglucagon-like peptide-1 receptorhumanshypoglycemiakidneyliraglutidemicroalbuminuriastandard of caretype 2 diabetes mellitus

Identifiers

PMID32132141
PMCPMC7133133
OpenAlexW3010392113

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.